Capecitabine and Temozolomide in NETs G1-2: The Experience of Various Hospitals in Spain Abstract #1389

Introduction: Treatment of neuroendocrine tumors (NETs) with capecitabine-temozolomide (CAPTEM) is an option yet to be confirmed in phase III trials.
Aim(s): The experience of 12 centers in Spain with this scheme is presented.
Materials and methods: We retrospectively reviewed patients with NETs G1-2 of any origin treated with capecitabine (750-1000 mg/m2 twice daily days 1-14) and temozolomide (150-200 mg/m2 days 10-14) every 28 days, from June 2009 to August 2015.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Chemotherapy
Presenting Author: Guillermo Crespo Herrero

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result